

Available online at [www.sciencedirect.com](www.sciencedirect.com/science/journal/10219498)

ScienceDirect

journal homepage: www.jfda-online.com

Original Article

Effect of high-pressure homogenization preparation on mean globule size and largediameter tail of oil-in-water injectable emulsions

Jie Peng, Wu-jun Dong, Ling Li, Jia-ming Xu, Du-jia Jin, Xue-jun Xia* , Yu -ling Liu †

Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing City Key Laboratory of Drug Delivery Technology and Novel Formulations, Beijing 100050, China

article info

Article history: Received 13 October 2014 Received in revised form 3 January 2015 Accepted 29 April 2015 Available online 19 May 2015

Keywords: high-pressure homogenization

mean droplet size large diameter tail of emulsions oil-in-water injectable emulsions over-processing

ABSTRACT

The effect of different high pressure homogenization energy input parameters on mean diameter droplet size (MDS) and droplets with $> 5 \mu m$ of lipid injectable emulsions were evaluated. All emulsions were prepared at different water bath temperatures or at different rotation speeds and rotor-stator system times, and using different homogenization pressures and numbers of high-pressure system recirculations. The MDS and polydispersity index (PI) value of the emulsions were determined using the dynamic light scattering (DLS) method, and large-diameter tail assessments were performed using the light-obscuration/ single particle optical sensing (LO/SPOS) method. Using 1000 bar homogenization pressure and seven recirculations, the energy input parameters related to the rotor-stator system will not have an effect on the final particle size results. When rotor-stator system energy input parameters are fixed, homogenization pressure and recirculation will affect mean particle size and large diameter droplet. Particle size will decrease with increasing homogenization pressure from 400 bar to 1300 bar when homogenization recirculation is fixed; when the homogenization pressure is fixed at 1000 bar, the particle size of both MDS and percent of fat droplets exceeding 5 μ m (PFAT₅) will decrease with increasing homogenization recirculations, MDS dropped to 173 nm after five cycles and maintained this level, volume-weighted PFAT₅ will drop to 0.038% after three cycles, so the "plateau" of MDS will come up later than that of PFAT $_5$, and the optimal particle size is produced when both of them remained at plateau. Excess homogenization recirculation such as nine times under the 1000 bar may lead to PFAT₅ increase to 0.060% rather than a decrease; therefore, the high-pressure homogenization procedure is the key factor affecting the particle size distribution of emulsions. Varying storage conditions (4-25°C) also influenced particle size, especially the PFAT₅. Copyright © 2015, Food and Drug Administration, Taiwan. Published by Elsevier Taiwan LLC. Open access under [CC BY-NC-ND license.](http://creativecommons.org/licenses/by-nc-nd/4.0/)

E-mail addresses: xjxia@imm.ac.cn (X.-j. Xia), ylliu@imm.ac.cn (Y.-l. Liu).

<http://dx.doi.org/10.1016/j.jfda.2015.04.004>

1021-9498/Copyright © 2015, Food and Drug Administration, Taiwan. Published by Elsevier Taiwan LLC. Open access unde[r CC BY-NC-ND license.](http://creativecommons.org/licenses/by-nc-nd/4.0/)

^{*} Corresponding author. Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing City Key Laboratory of Drug Delivery Technology and Novel Formulations, Beijing 100050, China.

^{**} Corresponding author. Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing City Key Laboratory of Drug Delivery Technology and Novel Formulations, Beijing 100050, China.

1. Introduction

An emulsion is defined as "a system comprised of two immiscible liquids, one of which is dispersed as droplet (the dispersed or internal phase) throughout the other (the continuous or external phase)" [\[1\]](#page-7-0). An oil-in-water emulsion contains small oil droplets dispersed within a watery continuous phase, with each oil droplet surrounded by a protective coating of emulsifier molecules [\[2\]](#page-7-0). Clinically, lipid emulsions are mostly administrated by intravenous injection, and are commonly used for patients who require parenteral nutrition as a source of essential fatty acids. Lipid emulsions have recently been used as drug delivery vehicles for poorly soluble drugs. The quality control indicators of lipid-injectable emulsions include appearance, particle size and size distribution, pH value, Zeta potential and lipid oxidization. Particle size plays a key role in many emulsion properties such as appearance, rheology, color, texture, stability, and shelf-life [\[3\]](#page-7-0); various factors such as the formulation design including the selection of oil phase, water phase and emulsifier, and even the container of emulsions [\[4\]](#page-7-0) may have an effect on particle size and size distribution. To produce emulsions with fine particle size and narrow size distribution, either a large amount of energy or surfactant or the combination of both is required. There are two methods to produce emulsions: lowenergy emulsification and high-energy emulsification. Lowenergy emulsification methods, such as the phase inversion temperature technique, involve transitional inversion induced by changing factors that affect the hydrophilic lipophilic balance (HLB) of the system [\[5,6\].](#page-7-0) This method has several limitations, including requiring a large amount of surfactants during preparation, and it cannot be used for large-scale industrial production [\[1\]](#page-7-0). High-energy emulsification utilizes mechanical devices such as high-pressure homogenizers, microfluidizers, and sonication methods, which can generate intense disruptive forces that break up the oil and water phases and lead to the formation of tiny oil droplets [\[7\]](#page-7-0). High-energy emulsification methods are applicable to industrial operations because there is flexible control of emulsion droplet size distributions, and the energy needed can generally be achieved in high-pressure systems [\[1\].](#page-7-0) In laboratory studies and most emulsion preparations, it is more efficient and convenient to produce emulsions in two steps: (1) conversion of separate oil and water phases into a coarse emulsion usually through rotor-stator devices; and (2) the final fine emulsion is then prepared using high-pressure systems.

Mean droplet size and size distribution are two significant parameters during lipid injectable emulsion preparation procedures [\[8,9\]](#page-7-0). In addition, fat droplets with diameters larger than 5 μ m in injectable emulsions should also be taken into account because they are associated with emulsion stability and safety. When the volume-weighted percent of fat droplets exceeding 5 μ m (PFAT₅) exceed 0.4%, phase separation is visually observed $[10]$; however, a large PFAT₅ can also cause safety problems, such as emboli in the lungs and abnormal liver function $[11-13]$ $[11-13]$. The United States Pharmacopeia (USP) emphasizes that "these two regions of the globule size distribution (MDS and $PFAT_5$) must be controlled within specified

limits" [\[14\].](#page-7-0) The USP has proposed specific globule size distribution limits in Chapter 729 [\[14\]](#page-7-0). It recommends two methods for particle size determination: Method I and Method II. Method I involves light-scattering techniques that are used for determination of the mean droplet size in lipid injectable emulsions, and MDS should not exceed 500 nm. Method II is a light obscuration (LO) or light extinction (LE) method that is used to determine the extent of the large-diameter droplet tail ($> 5 \mu m$) in lipid-injectable emulsions, and PFAT₅ should not exceed 0.05% of the total lipid component.

MDS tends to decrease with increasing homogenization pressure and recirculation, but interestingly, higher pressures with longer emulsification times may lead to overprocessing, which may result in increased MDS $[1,2,15-17]$ $[1,2,15-17]$. However, the influence of overprocessing on $PFAT₅$ has not been evaluated, because researchers have previously focused on the behavior of mean particle size rather than large droplet size. The aim of this study is to systematically examine the influence of the rotor-stator system, homogenization pressure, homogenization cycles, interval place time and different storage conditions on MDS and PFAT₅, and to determine the key factor that affects MDS and PFAT₅ during the emulsion preparation procedures.

2. Materials and methods

2.1. Materials

Soybean oil (long chain triglyceride; LCT) and medium chain triglyceride (MCT) were supplied by Zhonghang Pharmaceutical Company (LCT: Lot No. 13060105-2-01; MCT: Lot No. 120901-2-01, Tieling, China). Cholesterol was purchased from Nanjing Xinbai Pharmacy (Lot No. 121201, Nanjing, China). Glycerol was purchased from Jiahe Biotechnology Company (Lot No. 131207, Shantou, China). Poloxamer 188 was purchased from BASF Company (Lot No. WPCH530B, Germany). Soybean lecithin was purchased from Toshisun Biology & Technology Corporation (Lot No. 560400-2130332-01, Lipoid GmbH, Germany). Hydrochloric acid was supplied by Beijing Chemical Works (Lot No. 20140316, Beijing, China). Double distilled water was used for the preparation of all solutions.

2.2. Preparation of the emulsions

Our laboratory had developed a novel Cremophor-free, autoclave stable, intravenous emulsion for paclitaxel, a paclitaxel-cholesterol complex was used as the drug carrier to improve the solubility of paclitaxel in the oil phase of emulsions [\[18\].](#page-7-0) Based on the existing ingredients and produce process of paclitaxel emulsions, the blank paclitaxel emulsions (without drug) would become the test object. At first, the cholesterol was dissolved in 20% MCT/LCT (mean chain triglyceride/soybean oil = 1:1 by mass) at 60 \degree C. Next, the aqueous phase consisting of soybean lecithin, poloxamer 188, and glycerol was uniformly dispersed at 60° C in a water bath. Then, the coarse emulsion was prepared at 60° C with high shear mixing using a Fluko homogenizer FA25 model (Fluko Equipment Shanghai Co. Ltd., China) by rapidly adding the oil phase to the aqueous phase at 10,000 rpm. The high shear mixing process was carried out for 8 minutes at 19,000 rpm and the final emulsion was obtained by high-pressure homogenization using homogenization equipment (APV-2000, Germany) at 1000 bar for seven cycles. The temperature of the whole homogenization process was maintained below 40° C in a cycle ice-water bath. The pH value was adjusted to 4.5 with 0.1M hydrochloric acid and the emulsion was finally transferred to vials and autoclaved using an autoclave (ZDX-35SBI, Shen'an Medical Instruments, Shanghai) at 115°C for 30 minutes.

2.3. Study design

Batches of emulsions were prepared using the same ingredients and different technological parameters. Coarse emulsions were prepared at different temperatures (25°C, 40° C, and 60° C). The oil was homogenized to the aqueous phase using an Ultra Turrax model. In this process, different coarse emulsions were prepared using varying the rotation speeds (from 13,000 rpm to 19,000 rpm) or rotation times (from 4 minutes to 8 minutes). A batch of coarse emulsion (water bath temperature: 60° C, rotation speed: 19,000 rpm, rotation time: 8 minutes) was placed for different times $(30-120$ minutes) to simulate the interruption accidentally during emulsion preparation, and then passed through a high-pressure homogenizer. Parts of coarse emulsions were homogenized using seven cycles but under different pressures in the range of $400-1300$ bar, and other parts were homogenized under 1000 bar using different homogenization recirculations, from one to nine times. The homogenizing chamber was cooled using a cooling jacket containing cold water at approximately 5° C, to slow the rise in temperature. The pH of each emulsion was adjusted to 4.5 using 0.1M HCl. After nitrogen purging, emulsions were aliquoted into several cylindrical glass tubes (volume, 10 mL; internal diameter, 20 mm; height, 40 mm) and sterilization at 115° C for 30 minutes using an autoclave. Each emulsion was carefully collected and stored at 4°C before particle size analysis. All factors that may affect the particle size were investigated during emulsion preparation. The emulsions were prepared as described in [Table 1](#page-3-0).

The particle size (MDS and $PFAT_5$) of most emulsions were analyzed after storage at 4° C for 1 night. One batch of the emulsion (Lot No. 20140522-K), which was prepared using the standard technological parameters described earlier, was divided into several bottles. Some bottles were exposed to either the ambient environment or to high temperature (60 $^{\circ}$ C) for at least 10 days, and particle size was measured every 5 days. Other emulsion aliquots were stored at 4°C, 15°C, or 25°C for at least 2 months, and particle size was measured for each month.

2.4. Analytical methods

The MDS and polydispersity index (PI) value of the emulsions were determined using the dynamic light scattering (DLS) method. The PI is an important parameter that can reflect the state of emulsion particle size distribution; a smaller PI value indicates a more concentrated particle size distribution. Usually both the MDS and PI are required to reflect the mean emulsion particle size. The diffractometer model used was the NiComp 380ZLS submicron particle sizer and the Zeta potential analyzer subsystem (Particle Sizing Systems, Santa Barbara, CA, USA) was equipped with 635 nm red laser diode and high-gain photomultiplier (PMT) detector, which detected sizes ranging from 0.5 nm to 6 μ m. The emulsion was diluted to about 1/500 with distilled water in the diffractometer cell, stirred, and the diluted emulsion was measured for at least 5 minutes. Measurements were repeated twice for each sample. The diluted sample particle dispersed in solvent because the suspended particles move randomly as a result of brownian motion. A monochromatic coherent laser beam irradiated the suspension, the time scale of the fluctuation of scattering light intensity is dependent on the size of the particle. A small particle will "jitter" about in the solution relatively rapidly, resulting in a rapidly fluctuating intensity signal; by contrast, large particles will diffuse more slowly, resulting in a more slowly varying intensity. A fluctuating intensity signal is collected by the PMT detector at a certain angle, such as 90, and it can "transport" the fluctuating intensity signal to the digital correlation processor. The diffusion coefficient D can then be obtained. From D, we can calculate the particle radius R using the well-known Stokes-Einstein relation:

$$
D = k T/6\pi \eta R \tag{1}
$$

where k is Boltzmann constant (1.38 \times 10^{–16} erg K^{–1}), T is the temperature (K = $°C +273$) and η 2is the shear viscosity of the solvent (e.g., η he she \times 10⁻² poise for water at 20°C).

The large-diameter tail assessments were performed using the light-obscuration/single particle optical sensing (LO/SPOS) method. The AccuSizer 780APS automatic particle sizer (Particle Sizing Systems, Santa Barbara, CA, USA), equipped with an automatic dilution system and connected to a LE400-05 sensor in extinction mode that was previously calibrated using polystyrene latex spheres, was used to detect the largediameter tails. The emulsion samples were removed from each container using an automatic bottle sampler and transferred to the dilution system. The applied dilution factor was set according to the oil concentration of each product to achieve an acceptable level of cumulative particle counts, which was approximately one third of the coincidence limit of the sensor (9000 particles/mL). Samples were run at least in triplicate and the mean value is reported. The calculations and technique for employing a particle counter to assess the number of large oil droplets present in a lipid emulsion have been described elsewhere [\[19,20\]](#page-7-0). Normalization of the data requires converting the results for each size channel to its equivalent spherical volume (ESV) using the following formula:

$$
ESV = (\pi \times D^3)/6 \tag{2}
$$

where D is the diameter in centimeters of each size channel and ESV is expressed in cubic centimeters (cm^3). The number of particles is then multiplied by the ESV yielding a calculated total spherical volume (TSV) for a given channel of data:

 b Time 2: the delayed time of homogenization emulsions for autoclaved.</sup>

$$
TSV = number of particles \times ESV
$$
 (3)

The percentage of the fat concentration in the injectable emulsion formulations that exists as enlarged lipid globules is then calculated using the following formula:

$$
\% \text{Pat} = 100 \times \frac{\text{TSV}(\text{cm}^3) \times \text{density}(g/\text{mL}) \times \text{dilution factor}}{\text{sample volume}(\text{cm}^3) \times \text{fat composition}(g/\text{mL})}
$$
\n(4)

where the density of LCT/MCT is equal to 0.93 g/mL. The $PFAT_5$ value was calculated from data for the size distribution of globules $>$ 5 μ m.

3. Results and discussion

The emulsion energy input parameters included water bath temperature, rotation speed, and time, which were related to coarse emulsion preparation, and homogenization pressure and recirculation, which were related to homogenization procedures. These parameters were chosen based on a previous study: rotation speed, exposure time, gap distance, and disk design where energy input parameters belonging to rotor-stator systems, and homogenization pressure, recirculation, and nozzle design belonged to the high-pressure systems [\[1\]](#page-7-0). Because the shearing head and homogenization machine are fixed, the gap distance, and the disk design and nozzle design are constant, the remaining parameters represent the key steps in whole emulsion preparation. The influence of different coarse emulsion and homogenization emulsion times on particle size was taken into consideration because, during emulsions preparation, coarse emulsions could not be homogenized or emulsions could not be nitrogen sealed in time. This was inevitable because of equipment failure, power failure, and other emergencies. Prepared emulsions presented as a milky liquid with a white color appearance, and the MDS, PI, and $PFAT₅$ were examined in the current study. The results for the course emulsion preparation process are presented in [Table 2](#page-4-0). Altering any of the three parameters (water bath temperature, rotation speed, and rotation time) resulted in a PFAT $_5$ value that ranged from 0.035% to 0.042%, a MDS that ranged from 170 nm to 180 nm, and a PI that fluctuated from 0.1 to 0.2. Changing the energy input parameters related to coarse emulsion seems to have almost no influence on MDS and the PFAT $_5$ value. We can ensure that altering the process of making coarse emulsions will not affect the MDS and $PFAT₅$ value, because there was a large decrease in the particle size when the coarse emulsions were passed through the high-pressure homogenization under certain pressures.

To investigate the influence of exposure to ambient temperatures for a period of time on coarse emulsion particle size $(MDS$ and $PFAT₅$), a batch of coarse emulsion was exposed to air at ambient temperature (with the cap cover in place to prevent contamination of the emulsion) for 30 minutes, 60 minutes, or 120 minutes, and then homogenized in chrono-logical order. The results are presented in [Table 2.](#page-4-0) The PFAT $_5$ value was close to 0.038%, within a fluctuation range of 0.04%. The MDS values were approximately 170 nm and the PI values were approximately 0.1. Many factors (such as determinative error) were taken into account, and there was almost no influence on MDS and the $PFAT₅$ value when the coarse emulsion was incubated at ambient temperature for 120 minutes before homogenization. The coarse emulsion was incubated

Table 2 – The particle size results of changing technical parameters that were related to the process of coarse .
emulsions prepared.

for different lengths of time, then passed for seven cycles under 1000 bar pressure. The MDS and $PFAT₅$ values are presented in Fig. 1. The mean droplet diameter decreased from 2373 nm when rotation ended to 168.7 nm after homogenization, 2373 nm after 30-minute incubation to 174.3 nm after homogenization, 1600 nm after 60-minute incubation to 177.9 nm after homogenization, and 1526 nm after 120-minute incubation to 166.5 nm after homogenization. The PFAT₅ value before homogenization was as high as 117%. It was 117% after 30-minute incubation, 109% after 60-minute incubation, and 96% after 120-minute incubation, and this PFAT₅ value decreased to 0.038%, 0.037%, 0.034%, and 0.042%, respectively, after homogenization. These results indicate that homogenization is particularly efficient at forming small droplet sizes in emulsions, and droplet disruption in rotor-stator systems is generally less efficient than high-pressure devices. Because the dispersing zones of rotor-stator systems usually have larger volumes, at constant energy density and volume flow rate, the mean power density in rotor-stator systems is lower than that in the nozzles of high-pressure devices [\[21\]](#page-7-0). No matter how coarse the emulsion is, when it was passed through the same homogenization recirculation under the same homogenization pressures, the same fine levels in both PFAT₅ and MDS can be attained. However, the rotor-stator system is still important because it can efficiently convert separate oil and water phases into macroemulsions with a fairly large droplet size to alleviate the wear and tear on the homogenizer. The Ultra Turrax model was widely used during emulsions preparation because it is simple to operate and it can produce a good dispersing effect at a low shear force (Table 2, Fig. 1).

During the high-pressure homogenization, emulsions were produced using a fixed number of seven homogenization cycles and the homogenization pressure was varied

Fig. 1 – The comparison of particle size of emulsions, which was measured before and after homogenization under 1000 bar. (A) The mean droplet size (MDS) value of emulsions that was measured before and after homogenization. (B) The volume-weighted percent of fat droplets exceeding 5 μ m (PFAT₅) value of emulsions that was measured before and after homogenization.

from 400 bar to 1300 bar. The MDS and PFAT₅ values are presented in [Table 3](#page-5-0). The PFAT $₅$ value of emulsions under</sub> 400 bar homogenization pressure was as high as 0.157%, which was almost three times the large diameter limit of 0.05%, and the mean droplet size increased to approximately 300 nm. The results showed that low pressure cannot produce a fine emulsion, and that MDS and the PFAT $₅$ value</sub> decrease with increasing homogenization pressure, whereas the value of PI remained at approximately the same level from 400 bar to 1300 bar. The results showed that increasing the homogenization pressure is an effective way to reduce the particle size for both MDS and $PFAT_5$, and the value of PI may be dependent on homogenization recirculation rather than homogenization pressure. The MDS and $PFAT₅$ value of the emulsions that were produced under 1000 bar homogenization pressure but using different numbers of homogenization recirculations (from 1 to 9) is presented in [Table 3](#page-5-0). When the results of a previous study are included, the PFAT₅ value of coarse emulsions was 117%. For the emulsion that was passed for one cycle under 1000 bar, the PFAT₅ decreased to 0.129%, which illustrated that high-pressure homogenization is particularly efficient at breaking large droplets into small ones. However, 0.129% was still above the PFAT₅ standard of 0.05%, and homogenizing only one cycle at very high pressure was not enough to form emulsions with an appropriate particle size; multiple recirculations were required to make fine emulsions. Results showed that after three cycles, the coarse emulsions $PFAT₅$ value was 0.039%. Increasing the recirculation times from five to nine

 MDS = mean diameter droplet size; PFAT₅% = percent of fat droplets exceeding 5 μ m; PI = polydispersity index; SD = standard deviation.

^a The value of some bottles is 0.060%.

^b The value of some bottles is 0.083%.

maintained the PFAT $₅$ value at 0.038%, and it fluctuated</sub> within a narrow range. The value of MDS decreased from 270.3 nm to 173.4 nm after five homogenization cycles, and stabilized around 174 nm as the number of recirculations increased. The PI value decreased as the number of recirculations increased. MDS and $PFAT₅$ results indicated three key messages: (1) the value of MDS and $PFAT₅$ decreases as the number of homogenization recirculations increases. After a certain number of recirculations, particle size does not decrease further, and the particle size will remain at a certain value and fluctuate within a narrow range; (2) the PFAT₅
"plateau" appeared earlier than the MDS value "plateau"; and (3) the PI was inversely related to homogenization recirculation. To illustrate that this is not a random phenomenon, one batch of emulsions was prepared using a homogenization pressure of 700 bar (Table 3). The PFAT₅ value was stable after three cycles, the MDS was stable after seven cycles, and the value of PI decreased as the recirculation increased, which is in agreement with previous studies that used a pressure of 1000 bar. Emulsions with suitable MDS and PFAT5 values can be prepared under appropriate homogenization pressure and recirculation. High pressure can produce fine emulsions, and multiple homogenization recirculations can decrease particle size further, but the particle size will not change after a certain number of homogenization cycles using high pressure. Both homogenization pressure and recirculation were required to be assessed, and proper recirculation could produce suitable MDS and $PFAT₅$ values. Interestingly, in the process of particle size measurement, results from the same batch of emulsions may be different between different aliquots. The PFAT $₅$ value of some emul-</sub> sion aliquots, which was produced under 1000 bar within nine cycles, increased quickly to 0.060%. When the same preparation process was repeated, the phenomenon stayed the same. This situation was also present in the emulsion that was produced under 700 bar within nine cycles; the $PFAT₅$ of some aliquots increased to 0.083%, whereas the situation was not present in the emulsion that was produced using other, lower homogenization pressures. Commercially available emulsions also exhibit the phenomenon that large droplet size in the same batch of emulsions may be different between different aliquots. This suggests that too many homogenization recirculations may increase the PFAT $₅$ value</sub> rather than decrease the PFAT₅ value under high pressure. As the homogenization pressure increases, an increased $PFAT₅$ value produced by repeated recirculation will become more and more common. This situation likely occurred as a result of ultra-high pressures that did not seem to benefit emulsification efficiency because of high recoalescence rates $[1,2,15-17]$ $[1,2,15-17]$ $[1,2,15-17]$. The emulsions droplet size is the result of equilibrium between the droplet breakup and recoalescence [\[1\].](#page-7-0) Between new droplet formation and its subsequent encounter with surrounding droplets, surfactants adsorb onto the created interface to prevent its recoalescence. If the timescale of surfactant absorption is longer than the timescale of collision, the fresh interface will not be completely covered and this will lead to recoalescence. This means that although the energy input during emulsification has been increased, the obtained emulsions have a larger droplet size rather than the expected smaller sizes. This phenomenon is called overprocessing [\[1\].](#page-7-0) Previous research demonstrated the overprocessing phenomenon through measuring the MDS value, and now the overprocessing may influence the PFAT₅ value. It needs to be stressed that the phenomenon of increased MDS that results from overprocessing was not a certainty, and there is a certain size below which MDS cannot be reduced with repeated emulsification. An increase in MDS can be caused by poor stabilization of the newly formed droplets and is also a result of overprocessing [\[1\].](#page-7-0) In this research, the MDS did not increase with repeated emulsification. The value fluctuated around 170 nm, and this value was smaller than that of the commercially available emulsions, because poloxamer was added to our emulsions. This may also explain why there was no overprocessing after repeated homogenization recirculations.

To determine whether sterilization in time is vital to emulsion particle size, three batches of emulsions were homogenized and then sterilized after a delay of 30 minutes, 60 minutes, or 120 minutes. The particle size results are presented in Table 3. There was almost no difference in the particle size (MDS and $PFAT_5$) of emulsions compared with the particle size of the emulsion that was autoclaved immediately after homogenization. The results indicate that the emulsion particle size after homogenization is stable within 120 minutes when it is exposed to the ambient environment without sterilization (Table 3).

The storage instructions for the commercially available emulsions are to refrigerate below 25°C but not to freeze. Each

bottle of commercially available emulsions were nitrogen filled and had a leak-proof seal to prevent air from entering the container. The recommended storage conditions indicated that air and temperature are important for particle size of injectable emulsions. To test whether the air and temperature are significant to particle size, the same emulsions were either stored at different storage temperatures or exposed to the air for a long duration. Before particle size measurement, appearance was checked. Emulsions were a milky liquid, and there was no appearance difference between the original and after exposure to air. MDS and PFAT $₅$ results of emulsions</sub> exposed to air for 10 days are presented in Table 4. There was no significant change in mean droplet size and large droplet size. Oxidation had no influence on particle size when exposed for 10 days, as assessed using both MDS and $PFAT_5$; the results also indicated that if the emulsion has a smaller MDS and PFAT5, particle size is more stable for an extended period when it is exposed to air. A previous study showed that lipid oxidation can be accelerated by reactions that take place at the surface of the emulsion droplets. Therefore, the rate of lipid oxidation should increase as the droplet size decreases, because smaller droplets expose a larger surface area per unit volume to the pro-oxidants at the interface [\[22,23\]](#page-7-0). Assessing the fine particle size only and not other quality control indicators such as lipid oxidation is a limitation. The emulsions were exposed to air for a period of time, and although the particle size did not change, the peroxide value increased over time. Peroxide can cause cardiovascular disease and cancer, and nitrogen gas sealing is an essential link during emulsion preparation because it can reduce the amount of peroxide generated (Table 4).

The emulsion appearance did not change after storage at a high temperature (60 $^{\circ}$ C) for 10 days. The particle size results are presented in Table 4. The PFAT₅ value increased from 0.038% to 0.052%, suggesting that high temperatures significantly affect the $PFAT_5$ value within a short time. The particle size results of emulsions that were stored under different

temperature conditions are presented in Table 5. There was almost no change in the MDS and PFAT₅ values after storage at 4° C and 15 $^{\circ}$ C for 1 month, whereas the PFAT₅ value of the emulsion that was stored at 25°C for 1 month increased from 0.038% to 0.101%. The recommended temperature of many commercial emulsions is below 25°C. However, this temperature range may be too wide, because the particle size, especially PFAT₅, was not stable. Additionally, low temperature may prevent greater oxidation [\[17\]](#page-7-0), so a more rigorous storage temperature range such as below 15°C would be beneficial to extend the storage life (Table 5).

In conclusion, based on existing formulation (without drug) of emulsions, changing the energy parameters that relate to the coarse emulsion process has no influence on MDS and PFAT₅, and the key factors are homogenization pressure and recirculation. When the homogenization recirculation was fixed, the value of MDS and $PFAT₅$ decreased with an increasing homogenization pressure. When the homogenization pressure was fixed, the PFAT₅ value may reach the minimum after several recirculations (such as 3 cycles), and it will remain at this level even if the recirculation number is increased. The MDS "plateau" will emerge later than that of PFAT₅, and the optimal particle size is produced when both MDS and PFAT₅ remained at the plateau. It should be noted that too much homogenization recirculation under high pressure may amplify the value of MDS and PFAT₅ because of overprocessing. The formulation of paclitaxel-loaded emulsions was also investigated, and there are some difference between blank emulsions and drug-loaded emulsions in the specific value of particle size, size distribution, and large diameter particle, but the trend of particle size varying with processing technical parameter did not have any alteration. Thus, it is better to screen the homogenization pressure and recirculation to obtain the desired particle size. To maintain the optimal particle size, MDS, and $PFAT₅$ as long as possible, the emulsions should be well sealed using nitrogen and stored under 15°C refrigeration condition.

Conflicts of interest

The authors declare that there are no conflicts of interest.

Acknowledgments

This study was funded by the Committee of Pharmacopeia of China (1179) and the Basic Scientific Research Expenses of the Institute of Materia Medica (2013CHX09). The authors are grateful to Xue-jun Xia and Wu-jun Dong for providing experimental guidance and assistance.

references

- [1] [Jafari SM, Assadpoor E, He Y, Bhandari B. Re-coalescence of](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref1) [emulsion droplets during high-energy emulsification. Food](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref1) [Hydrocolloid 2008;22:1191](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref1)-[202.](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref1)
- [2] [Cheng Q, McClements DJ. Formation of nanoemulsions](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref2) [stabilized by model food-grade emulsifiers using high](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref2)[pressure homogenization: Factors affecting particle size.](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref2) [Food Hydrocolloid 2011;25:1000](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref2)-[8](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref2).
- [3] [McClements DJ. Food emulsions; principles, practice, and](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref3) [techniques. Boca Raton, FL: CRC Press; 2005](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref3).
- [4] [Wei L-J, Yu H-Y, Chang W-B, Lin C-H, Chen Y-C, Wu J-B.](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref4) [Effect of container on the physicochemical stability of](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref4) [propofol injectable emulsion after being diluted with 0.9%](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref4) [NaCl for intravenous infusion. J Food Drug Anal](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref4) $2013;21:421-5.$ $2013;21:421-5.$ $2013;21:421-5.$
- [5] [Izquierdo P, Esquena J, Tadros TF, Dederen C, Garcia MJ,](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref5) [Azemar N, Solans C. Formation and stability of nano](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref5)[emulsions prepared using the phase inversion temperature](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref5) [method. Langmuir 2002;18:26](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref5)-[30.](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref5)
- [6] [Tadros T, Izquierdo P, Esquena J, Solans C. Formation and](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref6) [stability of nano-emulsions. Adv Colloid Interfac](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref6) 2004:108-[09:303](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref6)-[18.](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref6)
- [7] [Gutierrez JM, Gonzalez C, Maestro A, Sol](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref7)e [I, Pey CM, Nolla J.](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref7) [Nanoemulsions: new applications and optimization of their](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref7) [preparation. Curr Opin Colloid In 2008;13:245](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref7)-[51.](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref7)
- [8] [Driscoll DF. Lipid injectable emulsions: pharmacopeial and](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref8) [safety issues. Pharmaceut Res 2006;23:1959](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref8)-[69.](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref8)
- [9] [Driscoll DF, Bistrian BR, Demmelmair H, Koletzko B.](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref9) [Pharmaceutical and clinical aspects of parenteral lipid](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref9) [emulsions in neonatology. Clin Nutr 2008;27:497](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref9)-[503.](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref9)
- [10] [Koster VS, Kuks PFM, Lange R, Talsma H. Particle size in](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref10) [parenteral fat emulsions, what are the true limitations? Int J](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref10) [Pharm 1996;134:235](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref10)-[8.](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref10)
- [11] [Driscoll DF, Ling PR, Bistrian BR. Pathological consequences](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref11) [to reticuloendothelial system organs following infusion of](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref11) [unstable all-in-one mixtures in rats. Clin Nutr](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref11) [2006;25:842](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref11)-[50](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref11).
- [12] [Driscoll DF. Quality, stability and safety of lipid emulsions.](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref12) Clin Nutr 2007:2:11-[5](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref12).
- [13] [Driscoll DF, Ling PR, Silvestri AP, Bistrian BR. Fine vs. coarse](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref13) [complete all-in-one admixture infusions over 96 hours in](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref13) [rats: Fat globule size and hepatic function. Clin Nutr](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref13) [2008;27:889](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref13)-[94](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref13).
- [14] [35th rev United States Pharmacopoeial Convention. General](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref14) [information chapter 729: globule size distribution in lipid](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref14) [injectable emulsions. 30th ed. Rockville, MD, USA: United](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref14) [States Pharmacopoeia Convention; 2008. p. 310](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref14)-[2.](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref14)
- [15] [Jafari SM, He YH, Bhandari B. Production of sub-micron](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref15) [emulsions by ultrasound and microfluidization techniques. J](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref15) [Food Eng 2007;82:478](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref15)-[88](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref15).
- [16] Desrumaux [A, Marcand J. Formation of sunflower oil](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref16) [emulsions stabilized by whey-proteins with high-pressure](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref16) [homogenization \(up to350 MPa\): effect of pressure on](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref16) [emulsion characteristics. Int J Food Sci Tech 2002;37:263](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref16)-[9.](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref16)
- [17] [Kuhn KR, Cunha RL. Flaxseed oil](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref17) $-$ [Whey protein isolate](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref17) [emulsions: Effect of high pressure homogenization. J Food](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref17) [Eng 2012;111:449](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref17)-[57](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref17).
- [18] [Xia XJ, Guo RF, Liu YL, Zhang PX, Zhou CP, Jin DJ, Wang RY.](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref18) [Formulation, characterization and hypersensitivity](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref18) [evaluation of an intravenous emulsion loaded with a](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref18) [paclitaxel](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref18)-[cholesterol complex. Chem Pharm Bull](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref18) [2011;59:321](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref18)-[6.](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref18)
- [19] [Thomas G, Pankaj P, Heather O. Physicochemical stability of](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref19) [lipid injectable emulsions: Correlating changes in large](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref19) [globule distributions with phase separation behavior. Int J](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref19) [Pharm 2007;343:208](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref19)-[19.](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref19)
- [20] [Driscoll DF, Ling PR, Bistrian BR. Pharmacopeial compliance](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref20) [of fish oil-containing parenteral lipid emulsion mixtures:](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref20) [globule size distribution \(GSD\) and fatty acid analyses. Int J](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref20) Pharm 2009:379:125-[30.](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref20)
- [21] [Stang M, Schuchmann H, Schubert H. Emulsification in high](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref21)[pressure homogenizers. Eng Life Sci 2001;1:151](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref21)-[7.](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref21)
- [22] [McClements DJ, Decker EA. Lipid oxidation in oil-in-water](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref22) [emulsions: impact of molecular environment on chemical](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref22) [reactions in heterogeneous food systems. J Food Sci](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref22) [2000;65:1270](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref22)-[82](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref22).
- [23] [Lee SJ, Choi SJ, Li Y, Decker EA, McClements DJ. Protein](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref23)[stabilized nanoemulsions and emulsions: comparison of](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref23) [physicochemical stability, lipid oxidation, and lipase](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref23) [digestibility. J Agr Food Chem 2011;59:415](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref23)-[27](http://refhub.elsevier.com/S1021-9498(15)00051-4/sref23).